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Abstract
Background: The importance of immuno-histological detection of neuroendocrine differentiation
in prostatic adenocarcinoma with respect to disease at presentation and Gleason grade is gaining
acceptance. There is limited literature on the relative significance of three commonly used markers
of NE differentiation i.e. Chromogranin A (CgA), Neuron specific enolase (NSE) and Synaptophysin
(Syn). In the current work we have assessed the correlation of immuno-histological detection of
neuroendocrine differentiation in prostatic adenocarcinoma with respect to disease at
presentation and Gleason grade and to determine the relative value of various markers.
Materials and methods: Consecutive samples of malignant prostatic specimens (Transurethral
resection of prostate or radical retropubic prostatectomy) from 84 patients between January 1991
and December 1998 were evaluated by immunohistochemical staining (PAP technique) using
selected neuroendocrine tumor markers i.e. Chromogranin A (CgA), Neuron specific enolase
(NSE), and Synaptophysin (Syn). According to the stage at diagnosis, patients were divided into
three groups. Group (i) included patients who had organ confined disease, group (ii) included
patients with locally invasive disease, and group (iii) with distant metastasis. NE expression was
correlated with Gleason sum and clinical stage at presentation and analyzed using Chi-Square test
and one way ANNOVA.
Results: The mean age of the patients was 70 ± 9.2 years. Group I had 14 patients, group II had
31 patients and group III had 39 patients. CgA was detected in 33 cases, Syn in 8 cases, and NSE in
44 cases. Expression of CgA was seen in 7% of group I, 37% in group II and 35% of group III patients
(p 0.059). CgA (p 0.024) and NSE (p 0.006) had a significantly higher expression with worsening
Gleason grade.
Conclusion: CgA has a better correlation with disease at presentation than other markers used.
Both NSE and CgA had increasing expression with worsening histological grade this correlation has
a potential for use as a prognostic indicator. Limitations in the current work included small number
and retrospective nature of work. The findings of this work needs validation in a larger cohort.
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Background
Prostate cancer is the most commonly diagnosed malig-
nancy in men in the United States with an estimated
218,890 cases diagnosed in the year 2007 and estimated
death of 27,050 [1]. Among men, cancers of the prostate,
lung and bronchus, and colon and rectum account for
about 54% of all newly diagnosed cancers, prostate cancer
accounts for about 33% of cases in men [1]. Prostate can-
cer incidence rates continued to increase, although at a
slower rate than those reported for the early 1990s and
before. Based on cases diagnosed between 1995 and
2001, an estimated 91% of these new cases of prostate
cancer are expected to be diagnosed at local or regional
stages, for which 5-year relative survival approaches 100%
[1]. However, it is noteworthy that individual cancers
show substantial variation in its outcome. The variable
biological potential of these tumors makes it important to
stage the disease. The various prognostic indicators
include clinical staging, serum PSA, % biopsy core
involved and histological grade. The histological grade
correlates both with local invasiveness and the metastatic
potential. In a subset of both localized and locally
advanced cancers, the existing markers, however, are often
unable to differentiate poor from good outcome cancers.
On these grounds, it is important to establish validated
prognostic indicators that could help physicians in tailor-
ing treatment for individual patients.
Neuroendocrine (NE) differentiation in PC has received
increasing attention in the recent years due to prognostic
and therapeutic implications. The term NE differentiation
in prostatic carcinoma includes tumors composed exclu-
sively of NE cells (the rare and aggressive small cell carci-
noma and carcinoid/carcinoid like tumor) or, more
commonly, conventional prostatic adenocarcinoma with
focal NE differentiation [2]. The prognostic importance of
focal neuroendocrine differentiation in PC is controversial,
but current evidence suggests that it has an influence on
prognosis related to hormone resistant tumours or a role in
the conversion to a hormone resistant phenotype [3].
Various neuroendocrine markers like Chromogranin A
(CgA), synaptophysin (Syn), neuron specific enolase (NSE),
β HCG have been studied. However, CgA appears to be the
best overall tissue and serum marker [4]. In the current
study we have investigated the importance of immuno-his-
tological detection of neuroendocrine differentiation in
prostatic adenocarcinoma with respect to disease at presen-
tation and Gleason grade. In addition the relative signifi-
cance of three markers of NE differentiation i.e. CgA, NSE
and Syn is also correlated with stage and grade of disease.
Methods
This study was conducted following Aga Khan University's
ethical review committee (ERC) clearance, in view of the
nature of study; ERC waived the requirement for informed
consent. Consecutive malignant primary prostatic speci-
mens, were obtained from 84 patients by either trans-ure-
thral resection of prostate (n = 69 patients) for urinary
obstruction or from radical retro-pubic prostatectomy (n
= 15 patients) between January 1991 and December 1998.
These tissue specimens were taken from the archived
records of the department of pathology. The age ranged
from 52–93 years (mean 70 + 9.2 years). Sections were
stained for H & E as well as for Chromogranin A, Synap-
tophysin and NSE (DAKO), Glostrup, by immuno histo-
chemistry using PAP technique. The methods have also
been previously described in details [5]. Clinical staging
was done using the TNM system. For patients who had
radical retropubic prostatectomy, the T and N stage were
pathological and for patients who only had TURP was
radiological.
Briefly, 3 μm thick tissue sections were cut and mounted on
poly-L-lysine (sigma) coated slides. Sections were depar-
affinized in xylene and re-hydrated through graded alcohol
series followed by water. Sections were washed with water
followed by Phosphate buffer saline (PBS) rinse. Endog-
enous peroxidase in the sections was blocked for 30 min-
utes with 0.3% H2 02 in methanol. Sections were washed
with PBS. All sections were treated with Normal Swine
serum (NSS) prediluted 1:10 in PBS for 5 minutes.
The sections were then incubated with the primary anti-
bodies pre diluted appropriately in NSS for 90 minutes at
room temperature. Slides were then washed with PBS and
incubated with peroxidase-conjugated swine anti rabbit
secondary antibody (DAKO) at a dilution of 1:150 for 45
minutes at room temperature. This was followed by inocu-
lation with PAP complex. 3, 3'-diaminobenzidine (DAB)
was used as a final Chromogen. Harris Haemtoxylin was
used as a counter nuclear stain. Positive controls were used
with all batches of IHC staining. Same case by omitting the
primary antibody was used as a negative control with each
staining procedure. Histological grading, the Gleason sys-
tem, was used for grading of the cancer specimens; a senior
histopathologist (SP) blinded of previous Gleason grading
and clinical course performed rescoring. A consensus in
departmental consultation conference was achieved in case
of any discrepancy. Based upon the Gleason score patients
were divided into three groups i.e. well differentiated
(Gleason sum 2–4), moderately differentiated (Gleason
sum 5–7) and poorly differentiated (Gleason sum 8–10).
To study correlation and determine the p value Student t
was applied. Statistical significance was examined by
Mann-Whitney U-test, Student's t-test, Kruskal-Wallis test,
the log-rank test, and Simple regression. A P-value below
0.05 was considered to be significant.
Results
During the period of 1991–1998 there were 84 patients
with histological specimens from TURP and RRP. The
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mean age was 70 ± 9.3 years. Majority of patients had
either locally invasive (37%) or metastatic disease (45%)
and only 18% had organ confined disease. At a median
follow up of 8.4 ± 3.5 years 54% (n 45) were dead; of the
surviving 46% (n 39) 21 patients (25%) had metastatic
disease. There is a statistically significant difference in the
development of metastases, overall and cause specific sur-
vival between groups with and without CgA staining.
According to the TNM classification 35% (n = 29) had
stage T1, 32% (n = 29) stage T2, 25% (n = 21) stage T3 and
6% (n = 5) stage T4 disease according to the TNM classifi-
cation. Based upon the stage of the disease patients were
divided into three groups i.e. organ confined (T1-2),
locally invasive (T3-4 and N1) and metastatic (M1) can-
cer. Staining for NE marker (CgA) was seen in 39%, NSE
in 52% and Syn in only 10%. The % expression of the
three markers in the organ confined, locally advanced and
metastatic disease is shown in table 1. It is note worthy
that tumors with negative CgA staining were picked up in
the early stage with minimal or organ confined disease;
the positive results were obtained for locally advanced
and metastatic disease (p 0.059). The correlation is not
statistically significant but only shows a trend towards the
significance. The correlation between Gleason sum and %
expression of the three NE markers is shown in table 1. It
indicates modest (for CgA) to significant (NSE) relation-
ship between the extent of NE differentiation and Gleason
score. In table 2, significance of CgA and NSE is correlated
with overall, cancer specific survival and development of
metastatic disease. There was no significant correlation in
CgA, NSE and SYN expression with the androgen with-
drawal status.
Discussion and conclusion
In the present work we have shown NE differentiation in
conventional prostate adenocarcinoma and assessed the
relationship of the extent of NE status to the commonly
recognized prognostic variables. We have also tried to
evaluate the relative significance of immunohistochemi-
cally detected expression of three markers viz. CgA, SYN,
and NSE.
Prostate cancer is a leading cause of morbidity and mor-
tality in men, accounting for 33% of all new cases of can-
cer and 14% of deaths from cancer [1]. Despite
considerable advances in our ability to detect and treat
PC, there have been no significant corresponding
decreases in morbidity and mortality [6]. The therapeutic
aim is to tailor the approach to the clinical, morphologi-
cal, and molecular features of each patient. Many of the
clinically important predictive factors in PC are still
derived from a pathologist's examination of tissue speci-
mens using light microscopy, but the challenge of assem-
bling the information is such that the use of artificial
neural networks is expected to improve accuracy in diag-
nosis, staging, and treatment outcomes for PC [3,7]. PC
may show divergent differentiation towards a neuroendo-
crine phenotype in the form of neuroendocrine small cell
carcinoma or carcinoid-like tumours [8]. Much more
common, however, is focal neuroendocrine differentia-
tion in PC, which may be pronounced in about 10% of
carcinomas. The prognostic importance of focal neuroen-
Table 1: Clinical characteristics' of patients undergoing immunohistochemical analysis and the difference in various parameters 
between IHC expressed (+ve) and those that did not express IHC markers (-ve)
CgA+ve n = 
30
CgA -ve n = 
54
p value NSE +ve n = 
44
NSE -ve n = 
40
p value SYN +ve n 
= 8
SYN -ve n = 
76
p value
Age (median ±) 73.2 ± 6.3 69.1 ± 7.4 0.22 70.3 ± 7.4 68.4 ± 7.1 0.33 70.9 ± 9 71.2 ± 8.1 0.20
PSA mean 
(ng/ml)
432 310 0.10 606 444 0.10 112 412 0.01
Clinical stage 
Organ Confined
5 12 0.03 12 5 0.02 2 15 0.001
Locally 
Advanced
8 27 0.02 12 23 0.05 3 32 0.001
Metastatic 17 26 0.10 20 23 0.32 3 40 0.001
Gleason sum 
(mean)
6.9 6.1 0.05 6.1 7.2 0.04 7 6.3 0.22
CgA: Chromogranin A
NSE: Neuron specific enolase
SYN: Synaptophysin
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docrine differentiation in PC is controversial, but current
evidence suggests that it has an influence on prognosis
related to hormone resistant tumours or a role in the con-
version to a hormone resistant phenotype [3]. However,
we did not find a significant correlation in CgA, NSE and
SYN expression with the androgen withdrawal status. CgA
appears to be the best overall tissue and serum marker of
neuroendocrine differentiation, and thus serum CgA con-
centrations may be useful in assessing the emergence or
progression of hormone resistant cancer [8]. Recently
Kamiya et al noted that CgA had a stronger relationship
between serum levels and IHC positivity in contrast to
NSE, suggesting clinical usefulness as a tumor marker in
predicting the extent of neuroendocrine differentiation in
prostate cancer [9].
In our series CgA expression was seen in 31%, Synapto-
physin in only 8% and NSE in 45% cases. Only CgA
expression was significantly correlated with the clinical
stage of the disease, whereas both CgA and NSE correlated
with the grade. The significant relationship between
tumor grade and NE differentiation was found in some
studies [10-12] whereas other investigators failed to con-
firm [13,14]. In the present study there is a significant cor-
relation between rising Gleason sum and expression of
both CgA (p 0.024) and NSE (p 0.006). The relationship
between stage of the disease and NE expression was noted
only for CgA, whereas for both the other markers it was
not statistically significant.
We also compared CgA expression with established NE
markers used widely to identify NE cells and NED in the
prostate. CgA, a secreted acidic product of prostate NE
cells, is a widely accepted and specific marker of both NE
cell populations and NED differentiation [15,16]. NSE is
another classical NE marker, but lacks some specificity
compared to CgA. Serum concentrations of CgA and NSE
can be monitored as a potential prognostic factor in PCa
[17-19]. In tumor tissue, we found a statistically signifi-
cant correlation of CgA to NSE expression. Synapto-
physin, a presynaptic vesicle glycoprotein, is expressed in
virtually all cells of well-differentiated prostate NE tumors
(NET, carcinoid), neuroendocrine carcinomas (NEC), and
in poorly differentiated carcinomas including small cell
carcinoma (SCC), all being very rare clinic entities (0.2–
1%) [20]. However, SYN has a lower specificity for NE
cells than CgA and may stain positive in non-NE tumors
[21]. CgA seems to stain prostate NE cell populations
more homogenously than SYN.
Limitation in current work included small number of
patients which makes it to difficult to draw definite con-
clusions concerning the predictive value of various mark-
ers of NE differentiation in relation to disease progression
and survival. However, the trends are interesting and war-
rant further work in a larger cohort of patients.
In conclusion this study further supports the theory that
focal NE differentiation within classical prostate carci-
noma is predictive of poor prognosis, as it correlates with
Gleason sum and clinical stage of the disease. In our
study, CgA was the best predictor of NE differentiation as
it correlated better than the other two markers examined,
both with stage and grade of the disease. Given the rela-
tively small sample size of this study, these correlative
findings suggest that the prognostic impact of these mark-
ers merits further investigation in a larger cohort
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